



ASX/Media release

3 July 2007

AtCor signs US\$1.3 million new pharmaceutical contracts

- **Two major international pharmaceutical companies sign AtCor to monitor central blood pressures and arterial stiffness non-invasively in clinical trials**
- **Provides vital information about drug effects undetectable through traditional cuff blood pressure monitoring**

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures and arterial stiffness non-invasively, has signed agreements with two leading international pharmaceutical companies to supply SphygmoCor systems and clinical trial support services for new and ongoing drug trials in Europe and the United States. The total value of the contracts is approximately US \$1.3 million.

Duncan Ross, AtCor Medical chief executive officer said, "We are delighted to sign these technology and support services contracts with leading biopharmaceutical companies. SphygmoCor is the only FDA-cleared non-invasive technology to measure central blood pressures and assess arterial stiffness. This information is vital to clinical trials and patient care.

"Major clinical studies have proven that central blood pressure assessment reveals important drug effects that cannot be detected by traditional cuff blood pressure measurements. These studies show that elevated central pressure is a superior predictor of cardiovascular events such as heart attacks and strokes," he said.

About AtCor

AtCor Medical develops and markets products for the early detection and management of cardiovascular disease. More than 1,000 SphygmoCor systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies. AtCor has operations in Australia, the United States, and Europe. AtCor is listed on the ASX under code ACG. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au